Clearmind Medicine Inc., a clinical-stage pharmaceutical company, filed its unaudited condensed interim consolidated financial statements for the three months ended January 31, 2024, with the Canadian Securities Administration and relevant provincial commissions on March 18, 2024. The report, prepared in accordance with International Financial Reporting Standards, indicates a net loss of $1,367,800 for the period, a decrease from the previous year's loss of $1,899,469. Research costs decreased to $227,478 from $587,630, while general and administrative expenses also saw a reduction. The company reported significant developments, including a completed Type A meeting with the U.S. FDA regarding its clinical trial for the proprietary MEAI-based CMND-100 compound for Alcohol Use Disorder treatment. Clearmind also completed a registered direct and private placement for $2.4 million, and announced a...Show More

Clearmind Medicine Inc., a clinical-stage pharmaceutical company, filed its unaudited condensed interim consolidated financial statements for the three months ended January 31, 2024, with the Canadian Securities Administration and relevant provincial commissions on March 18, 2024. The report, prepared in accordance with International Financial Reporting Standards, indicates a net loss of $1,367,800 for the period, a decrease from the previous year's loss of $1,899,469. Research costs decreased to $227,478 from $587,630, while general and administrative expenses also saw a reduction. The company reported significant developments, including a completed Type A meeting with the U.S. FDA regarding its clinical trial for the proprietary MEAI-based CMND-100 compound for Alcohol Use Disorder treatment. Clearmind also completed a registered direct and private placement for $2.4 million, and announced a long-term licensing agreement with BIRAD of Bar-Ilan University for a cocaine addiction treatment. Additionally, the company received patent approval in China for its treatment of binge behaviors and submitted three patent applications under the PCT in collaboration with SciSparc Ltd. Clearmind also received approval from the Israeli Ministry of Health to commence a phase I/IIa clinical trial for AUD patients. The company's cash position improved, with cash on hand of $9,285,973 as of January 31, 2024, and it anticipates sufficient liquidity for at least twelve months. Clearmind Medicine Inc. is traded under the symbol 'CMND' on the Nasdaq and Frankfurt Stock Exchange.